Chlormethine: 6 agencies, 2017–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.”, while PBAC (Australia) recorded not recommended for “Mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL)”.
Assessment has run over 6 years, from 12 Jul 2017 at AWMSG (Wales) to 2023 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2023, recommended by 2023, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
2 of these 7 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess chlormethine, on 12 Jul 2017; PBAC (Australia) did not open a file until 2023 — a wide spread of 6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 4 years in total.
PBAC (Australia) is the only agency to have returned to chlormethine, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for chlormethine.
The full ledger for chlormethine reads 4 recommended, 1 not recommended, 1 restricted and 1 superseded.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2023 | Mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) | Not Recommended | source |
| DMC (Denmark) | 27 Oct 2022 | Topikal behandling af kutant T-celle-lymfom af typen mycosis fungoides | Anbefalet | source |
| TLV (Sweden) | 25 Apr 2022 | Ledaga ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| SMC (Scotland) | 10 May 2021 | Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. | accepted | source |
| HAS (France) | 13 Sep 2017 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
2 further decisions for chlormethine, across 2 agencies, are not shown here. They link to 1 further source document.
Related molecules
- bendamustine — same ATC class L01A — Antineoplastics
- temozolomide — same ATC class L01A — Antineoplastics
- busulfan — same ATC class L01A — Antineoplastics
- treosulfan — same ATC class L01A — Antineoplastics
- melphalan — same ATC class L01A — Antineoplastics
- carmustine — same ATC class L01A — Antineoplastics
Coverage: 7 decisions for chlormethine from 6 agencies, 2017 to 2023. Data to 7 Sep 2026. ATC class L01A — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.